Real-world effectiveness of guselkumab for induction of remission in Crohn's disease: a prospective multicenter cohort study with propensity score-matched comparison to risankizumab.

Crohns Colitis 360 · 2026 · PMC13316425 · PMID 42381756

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

a trend approaching significanceP = .066so close (0.05 < p ≤ 0.1)

No individual prior biologic class exposure significantly predicted remission ( Table S1 ), though prior vedolizumab exposure showed a trend approaching significance (OR 7.89, 95% CI, 1.21-156, P = .066) that was not confirmed on multivariable analysis (OR 6.12, 95% CI, 0.45-167, P = .20).

also in 74 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.